The overall prognosis for patients with pancreatic cancer is poor, with a median survival from diagnosis of 3 to 5 months, a 12-month survival rate of approximately 10%, and a 5-year survival rate of less than 5%. 2,3 Tumors arising from the distal common bile duct (CBD) and ampulla of Vater are rare tumors with clinical manifestations similar to those of pancreatic adenocarcinoma but with a slightly better prognosis. [4] [5] [6] [7] [8] Given the poor response of pancreatic adenocarcinoma to standard chemotherapeutic agents, other strategies, including immunotherapy, are being evaluated for the treatment of patients. Immunotherapeutic approaches for the treatment of pancreatic cancer include the identification and characterization of tumor antigens, which could serve as targets for immunotherapy. 9 Although pancreatic cancer-specific tumor markers are not available, several potential candidates have been identified by using the serial analysis of gene expression (SAGE) technology. 10 By using the online SAGE database (http://www.ncbi.nlm.gov/SAGE), the tag for mesothelin was present consistently in pancreatic cancer libraries but not in normal pancreas libraries. 11 Mesothelin is a 40-kd glycosyl phosphatidylinositollinked cell surface glycoprotein that is present on normal mesothelial cells lining the pleura, peritoneum, and pericardium. 12 The mesothelin gene encodes a 69-kd precursor protein that is processed to a 40-kd membrane-bound protein termed mesothelin and a 31-kd shed fragment called megakaryocyte potentiating factor. Mesothelin is the antigen recognized by monoclonal antibody (MAb) K1 that was generated by immunization of BALB/c mice with the human ovarian carcinoma cell line OVCAR-3. 13 Megakaryocyte potentiating factor was isolated
Mesothelin, a cell surface glycoprotein present on normal mesothelial cells, has been reported to be expressed in pancreatic adenocarcinomas. We conducted this study to fully characterize mesothelin expression in surgically resected
Pancreatic adenocarcinoma is the fourth leading cause of cancer-related death for men and women in the United States, with about an estimated 31,860 new cases diagnosed in 2004. 1 The overall prognosis for patients with pancreatic cancer is poor, with a median survival from diagnosis of 3 to 5 months, a 12-month survival rate of approximately 10%, and a 5-year survival rate of less than 5%. 2, 3 Tumors arising from the distal common bile duct (CBD) and ampulla of Vater are rare tumors with clinical manifestations similar to those of pancreatic adenocarcinoma but with a slightly better prognosis. [4] [5] [6] [7] [8] Given the poor response of pancreatic adenocarcinoma to standard chemotherapeutic agents, other strategies, including immunotherapy, are being evaluated for the treatment of patients. Immunotherapeutic approaches for the treatment of pancreatic cancer include the identification and characterization of tumor antigens, which could serve as targets for immunotherapy. 9 Although pancreatic cancer-specific tumor markers are not available, several potential candidates have been identified by using the serial analysis of gene expression (SAGE) technology. 10 By using the online SAGE database (http://www.ncbi.nlm.gov/SAGE), the tag for mesothelin was present consistently in pancreatic cancer libraries but not in normal pancreas libraries. 11 Mesothelin is a 40-kd glycosyl phosphatidylinositollinked cell surface glycoprotein that is present on normal mesothelial cells lining the pleura, peritoneum, and pericardium. 12 The mesothelin gene encodes a 69-kd precursor protein that is processed to a 40-kd membrane-bound protein termed mesothelin and a 31-kd shed fragment called megakaryocyte potentiating factor. Mesothelin is the antigen recognized by monoclonal antibody (MAb) K1 that was generated by immunization of BALB/c mice with the human ovarian carcinoma cell line OVCAR-3. 13 Megakaryocyte potentiating factor was isolated from the medium of a pancreatic cancer cell line and was noted to stimulate the megakaryocyte colony-forming activity of murine interleukin-3 in mouse bone marrow cultures. 14, 15 The biologic function of mesothelin is not known, although some studies suggest it might have a role in tumor spread. 16 Initial studies of mesothelin expression in human tumors were performed by immunostaining cryostat tissue sections with MAb K1. These studies demonstrated that mesothelin is overexpressed in several human malignant neoplasms, most notably nonmucinous ovarian cancer, epithelial mesotheliomas, and squamous cell carcinoma of the cervix, lung, and head and neck. 13, 17, 18 Since then, several studies have looked at mesothelin expression in formalin-fixed tissue samples of human cancers by immunohistochemical analysis using a commercially available antimesothelin MAb, 5B2 (Novocastra, Newcastle-upon-Tyne, England). These studies have confirmed mesothelin overexpression in nonmucinous epithelial ovarian cancer, epithelial mesotheliomas, and squamous cell carcinomas. [19] [20] [21] However, these studies, as well as gene expression studies, have shown that mesothelin also is overexpressed in pancreatic adenocarcinomas. 11, 20 The goal of our study was to carry out a detailed immunohistochemical analysis of mesothelin expression in 3 types of pancreaticobiliary adenocarcinomas: (1) ductal adenocarcinoma of the pancreas, (2) adenocarcinoma of the ampulla of Vater, and (3) adenocarcinoma of the CBD. We also studied the immunohistochemical expression of mesothelin in chronic pancreatitis, which occasionally can be difficult to distinguish from pancreatic adenocarcinoma in histologic sections. Mesothelin, besides being an emerging tumor marker for pancreaticobiliary adenocarcinomas, also is a promising target for cancer immunotherapy. 22 
Materials and Methods

Tissue Specimens
To study mesothelin expression by immunohistochemical analysis, archival, formalin-fixed, paraffin-embedded tissue blocks from patients with pancreaticobiliary tumors and chronic pancreatitis were obtained from the surgical pathology files of the University of Oklahoma, Oklahoma City. The institutional review board of the University of Oklahoma approved the study. The study group included 56 patients who had undergone pancreatic resection: 18 patients for pancreatic adenocarcinoma of ductal type, 9 for adenocarcinoma of the ampulla of Vater, 12 patients for CBD adenocarcinoma, and 17 for chronic pancreatitis. For the adenocarcinoma cases, the site of the tumor origin was determined by careful histopathologic and gross assessment of the specimens. All H&E-stained slides were reviewed, and representative slides from each case were selected for immunohistochemical studies. Of 18 pancreatic adenocarcinomas, 14 were well-or moderately differentiated, and the remaining 4 cases were poorly differentiated. One ampullar adenocarcinoma and 2 CBD adenocarcinomas were poorly differentiated, and the rest of the ampullar and CBD tumors were well-or moderately differentiated adenocarcinomas.
Immunohistochemical Analysis
Mesothelin expression in tumor specimens was evaluated by using immunohistochemical analysis. Briefly, 4-µm-thick tissue sections were cut from formalin-fixed, paraffin-embedded blocks onto Superfrost/Plus slides (Fisher Scientific, Fair Lawn, NJ); deparaffinized in xylene; rinsed in 100%, 95%, and 70% ethanol; and rehydrated in distilled water. The antigen was recovered by incubating the slides in 10 mmol/L of citrate buffer, pH 6.0, for 40 minutes in a vegetable steamer. Slides then were rinsed extensively in phosphate-buffered saline and incubated with blocking serum for 20 minutes. After excess blocking serum was shaken off, the slides were incubated with a 1:20 dilution of the mouse antimesothelin monoclonal antibody 5B2 overnight at 4°C. Endogenous biotin activity was blocked using an avidin D-biotin blocking solution before in situ localization of antigen using a biotinavidin antigen detection method (R.T.U. Vectastain kit, Vector Laboratories, Burlingame, CA). After extensive washing in phosphate-buffered saline, sections were incubated in a diaminobenzidine solution (Stable DAB, Invitrogen, Carlsbad, CA) and counterstained with a hematoxylin solution. Slides then were dehydrated by ethanol washing and cleared in xylene, and coverslips were placed on the slides. The slides were evaluated for intensity and extent of mesothelin staining.
Scoring of Mesothelin Immunoreactivity
Immunostained tissue sections were evaluated by 2 pathologists (Z.G.L and M.R.), and mesothelin expression was characterized by the percentage of tumor cells or pancreatic acinar cells that were mesothelin-positive. The cases with adenocarcinoma were categorized into 3 groups: negative, fewer than 1% of tumor cells stained for mesothelin; focally positive, 1% to 25% of tumor cells stained for mesothelin; and extensively positive, more than 25% of tumor cells stained for mesothelin. All tissue sections also were evaluated for intensity of mesothelin staining, which was graded as weak (1+), moderate (2+), or strong (3+).
Results
Mesothelin Expression in Pancreatic Ductal Adenocarcinoma
All 18 cases of pancreatic ductal adenocarcinoma showed mesothelin immunoreactivity. In 16 of 18 cases, mesothelin expression was noted in 50% or more of the tumor cells. Two cases had mesothelin expression in 25% of the tumor cells. Mesothelin immunostaining was moderate to strong intensity in 17 of 18 cases. Well-and moderately differentiated adenocarcinomas showed mesothelin positivity mostly along the apical membranes of the tumor cells. The cytoplasm of the tumor cells was negative or only slightly positive ❚Image 1A❚. Occasional tumor cells revealed large intracytoplasmic globular structures that were strongly positive for mesothelin ❚Image 2❚. Poorly differentiated adenocarcinomas also expressed mesothelin; however, the staining pattern was different from those of well-and moderately differentiated tumors. In contrast with the dominant apical membrane positivity in the better-differentiated cancers, poorly differentiated adenocarcinomas showed mesothelin positivity, along the cytoplasmic membranes and in the cytoplasm. Pancreatic intraepithelial neoplasia (PanIN) of various grades was identified readily in most of the specimens selected for immunohistochemical analysis, including those of chronic pancreatitis cases. Although no precise quantitative assessment of the PanIN lesions for mesothelin expression was performed, most of the PanIN lesions were negative for mesothelin expression. Occasional PanIN-1A and PanIN-1B lesions showed slight diffuse cytoplasmic mesothelin staining ❚Image 3A❚. A few PanIN-2 lesions revealed slight cytoplasmic and more prominent apical membrane mesothelin positivity ❚Image 3B❚. Virtually all PanIN-3 lesions were negative for mesothelin expression.
Mesothelin Expression in Adenocarcinoma of the Ampulla of Vater
We evaluated 9 cases of ampullar adenocarcinomas for mesothelin expression. Of the 9 cases, 8 showed mesothelin expression, with 50% or more of the tumor cells positive in 6 cases. Of the 8 positive cases, 7 had moderate to strong mesothelin staining. The staining patterns were similar to those observed in adenocarcinomas of the pancreas and the CBD.
Mesothelin Expression in Adenocarcinoma of the CBD
All 12 cases of CBD adenocarcinomas showed mesothelin expression, with 11 cases demonstrating mesothelin positivity in 50% or more of tumor cells. Ten tumors had moderate to strong signals, and 2 cases had a weak signal. The staining patterns were similar to those observed in the pancreatic ductal adenocarcinomas, ie, the better-differentiated adenocarcinomas showed mostly apical membrane staining, and the poorly differentiated tumors revealed membranous and cytoplasmic positivity. A case of mesothelin staining in CBD adenocarcinoma is shown in ❚Image 4❚.
Mesothelin Immunoreactivity of Normal Pancreatic Tissue
In all tissue sections with adenocarcinoma, mesothelin expression also was evaluated in the adjacent nonneoplastic pancreatic tissue. In 4 cases of pancreatic adenocarcinoma 
Mesothelin Expression in Chronic Pancreatitis
Tissue sections from 17 patients with chronic pancreatitis also were evaluated for mesothelin expression by immunohistochemical analysis. Of the 17 cases, 16 were negative ❚Table 2❚. In 1 case of chronic pancreatitis fewer than 5% of normal pancreatic ductal cells exhibited mild mesothelin positivity. ❚Image 5❚ shows a case of chronic pancreatitis with no mesothelin staining in the proliferating ducts or the surrounding pancreatic parenchyma.
Discussion
Mesothelin is a differentiation antigen present on normal mesothelial cells that is overexpressed in several human cancers. 12, 22 Initial immunohistochemical studies using MAb K1 showed that mesothelin is overexpressed in malignant mesotheliomas and nonmucinous ovarian carcinomas and in squamous cell carcinomas of the cervix, lung, and head and neck. 13, 17, 18 In these early studies, only 3 cases of pancreatic adenocarcinoma were evaluated, and these were all negative. 13 However, more recent studies of mesothelin expression by gene expression analysis and by immunohistochemical analysis using a newly described antimesothelin antibody, 5B2, revealed that mesothelin also is expressed in pancreatic adenocarcinoma. 11, 20, 21 Mesothelin expression at the gene and protein levels in pancreatic cancer was described by Argani and colleagues. 11 By using SAGE, the tag for mesothelin was consistently present in pancreatic cancer libraries but not in normal pancreas libraries. 11 Protein expression was confirmed by immunohistochemical analysis, using the antimesothelin monoclonal antibody, 5B2, in all 60 cases of resected primary pancreatic adenocarcinomas with intense labeling (3+) in 54 of 60 cases. In a study by Ordóñez, 20 mesothelin expression was evaluated in a wide variety of human tumors, including pancreaticobiliary tumors, using formalin-fixed, paraffin-embedded tissue samples and MAb 5B2. Of the 14 ductal adenocarcinomas of the pancreas examined, 12 were positive for mesothelin with strong and diffuse staining in 9 cases. All 3 cases of adenocarcinoma of the ampulla of Vater and 7 of 19 cholangiocarcinomas were positive.
A recent study showed that mesothelin gene expression is increased in ampullar adenocarcinomas. 23 This study also evaluated mesothelin expression at the protein level by immunohistochemical analysis. Tissue microarrays created from formalin-fixed, paraffin-embedded tumor blocks from 54 patients with ampullar adenocarcinoma and evaluated for mesothelin expression using MAb 5B2 showed that 66% of the tumors expressed mesothelin. Mesothelin expression using tissue microarrays also has been studied in biliary carcinomas. 24 Tissue microarrays were constructed using paraffin blocks from 10 intrahepatic cholangiocarcinomas, 15 distal CBD adenocarcinomas, and 13 gallbladder adenocarcinomas, and mesothelin expression was assessed by immunohistochemical analysis using MAb 5B2. Mesothelin expression was noted in 38%, 10%, and 80% of gallbladder adenocarcinomas, intrahepatic cholangiocarcinomas, and distal CBD adenocarcinomas, respectively. We conducted the present study to further characterize in detail mesothelin expression in various tumors of the pancreaticobiliary tree using whole tissue sections. In addition, mesothelin expression was evaluated in the adjacent "normal" pancreas from the tumor resection specimens and in sections obtained from patients with chronic pancreatitis. Of the 39 cases of pancreaticobiliary adenocarcinomas, 38 (97%) were positive for mesothelin expression. All 18 cases of pancreatic adenocarcinomas expressed mesothelin, with 16 cases exhibiting extensive/diffuse staining and 2 cases exhibiting focal positivity. All cases except 1 case with focally positive mesothelin expression had moderate to strong staining intensity.
Mesothelin immunoreactivity was noted in well-and poorly differentiated tumors. The characteristic pattern for mesothelin immunoreactivity is luminal membrane staining in well-and moderately differentiated carcinomas and membrane and cytoplasmic staining in poorly differentiated adenocarcinomas. Mesothelin expression was absent in benign proliferating pancreatic ducts in the tumorous and nontumorous portions of the pancreas. The nontumorous pancreatic acinar tissue adjacent to adenocarcinoma did not express mesothelin either.
A few ducts in cases with PanIN-1A and 1B lesions showed slight cytoplasmic mesothelin expression, whereas a few ducts with PanIN-2 lesions revealed slight cytoplasmic and more prominent apical membrane staining. However, none of the ducts with PanIN-3 lesions were positive for mesothelin expression.
Of the 9 cases of adenocarcinoma of the ampulla of Vater, 6 were diffusely positive for mesothelin expression, 2 were focally positive, and 1 was negative. For adenocarcinoma of the CBD, 11 of 12 cases showed diffuse positivity for mesothelin with strong staining intensity in 8 cases.
Mesothelin expression also was evaluated in 17 cases of chronic pancreatitis. All cases of chronic pancreatitis were negative for mesothelin expression, except 1 case that showed slight focal immunoreactivity of normal pancreatic ductal cells. Our results demonstrate that mesothelin is expressed in 100% of pancreatic adenocarcinomas, and these results are in agreement with the studies by Ordóñez 20 and Argani et al 11 that showed that 86% to 100% of pancreatic adenocarcinomas are positive for mesothelin. As in those 2 studies, the majority of our cases (89%) also had diffuse mesothelin immunoreactivity (>25% of tumor cells positive for mesothelin). The results of these 3 studies also are in agreement with immunostaining data using pancreatic tissue microarrays that showed mesothelin expression in 90% of pancreatic adenocarcinomas. 24 Only 1 previous study has evaluated mesothelin expression in tissue sections obtained from formalin-fixed, paraffinembedded blocks from patients with adenocarcinoma of the ampulla of Vater. 20 Of the 3 cases examined in that study, all were positive for mesothelin, with 2 cases having focal mesothelin positivity (<25% of tumor cells positive). However, a larger study of ampullar adenocarcinomas using tissue microarrays made from tumor blocks from 54 patients who underwent surgery for their cancer showed mesothelin positivity in 66% of cases. 23 Our study using tissue sections from 9 patients with ampulla of Vater adenocarcinoma showed mesothelin expression in 8 cases (89%), with 6 of those cases having diffuse immunoreactivity.
All 12 cases of adenocarcinoma of the CBD expressed mesothelin with diffuse staining in 11 of the tumors. These results are in contrast with the findings by Ordóñez in which only 7 (37%) of 19 cholangiocarcinomas were positive for mesothelin. 20 However, the site of origin of these tumors was not specified.
In a study of mesothelin expression in cholangiocarcinomas using tissue microarrays, mesothelin immunostaining was noted in 47% of the cases. 24 However, when the results were analyzed based on the site of the cholangiocarcinoma, 38% of gallbladder adenocarcinomas, 10% of intrahepatic adenocarcinomas, and 80% of distal CBD adenocarcinomas expressed mesothelin. Our results demonstrate that the majority of CBD adenocarcinomas express mesothelin, similar to the results seen in pancreatic adenocarcinoma.
To our knowledge, our study is the first published report evaluating mesothelin expression in chronic pancreatitis. All 17 cases of chronic pancreatitis were negative for mesothelin expression except 1 in which fewer than 5% of normal pancreatic ducts labeled for mesothelin. Therefore, mesothelin might be a useful marker in the pathologic diagnosis of pancreatic ductal adenocarcinoma because it is expressed in the majority of adenocarcinomas and absent in normal pancreas, chronic pancreatitis, and grade 3 PanIN. Mesothelin also could be a useful tumor marker for the diagnosis of adenocarcinomas of the ampulla of Vater and the CBD. Our study also supports the notion that in addition to its value in the pathologic diagnosis, mesothelin is an A B ❚Image 5❚ Chronic pancreatitis. The majority of the normal exocrine pancreatic parenchyma is replaced by prominent fibrosis admixed with surviving/proliferating benign ducts and a slight diffuse chronic inflammatory cell infiltrate. Note the complete lack of positivity in the proliferating ducts and in the surviving pancreatic (acinar) parenchyma (A, H&E, original magnification ×100; B, mesothelin immunostaining, original magnification ×100).
attractive candidate for targeted therapy of pancreaticobiliary cancers given its high expression in these tumors and absent expression in normal tissues except mesothelial cells. Clinical trials of a recombinant immunotoxin targeting mesothelin are ongoing, as are experimental studies to use mesothelin as a tumor vaccine. 22 
